Skip to main content
SpringerLink
Log in

Ivacaftor: A Review of Its Use in Patients with Cystic Fibrosis

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Ivacaftor (Kalydeco™) is a potentiator of the cystic fibrosis transmembrane conductance regulator (CFTR) and is the first drug that treats an underlying cause of cystic fibrosis to be licensed for use. Ivacaftor increases the open probability (i.e. gating) of CFTR channels with the G551D mutation, thus enhancing chloride transport, and is indicated in a number of countries for the treatment of cystic fibrosis in patients aged ≥6 years who carry this mutation. This review focuses on pharmacological, clinical efficacy and tolerability data relevant to the use of ivacaftor in this indication. In two 48-week, double-blind, phase III trials in patients aged ≥12 (STRIVE) or 6–11 (ENVISION) years with cystic fibrosis and the G551D mutation, oral ivacaftor 150 mg every 12 h significantly improved lung function relative to placebo, when used in combination with standard care. Significant improvements in pulmonary exacerbation risk (in STRIVE) as well as bodyweight and some aspects of health-related quality of life (both studies) were also seen with the drug versus placebo. Moreover, the beneficial effects of ivacaftor on parameters such as lung function and bodyweight were maintained over up to 96 weeks of treatment in an ongoing open-label extension of these studies. Ivacaftor was generally well tolerated, with headache, oropharyngeal pain, upper respiratory tract infection and nasal congestion being among the most common adverse events. Thus, ivacaftor expands the current treatment options for patients with cystic fibrosis who have the G551D mutation. Its potential for use in patients with other CFTR mutations is also of interest.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Pettit RS. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment. Ann Pharmacother. 2012;46(7–8):1065–75.

    Article  PubMed  Google Scholar 

  2. O’Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373(9678):1891–904.

    Article  PubMed  Google Scholar 

  3. Rogan MP, Stoltz DA, Hornick DB. Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment. Chest. 2011;139(6):1480–90.

    Article  PubMed  CAS  Google Scholar 

  4. Ratjen FA. Cystic fibrosis: pathogenesis and future treatment strategies. Respir Care. 2009;54(5):595–605.

    Article  PubMed  Google Scholar 

  5. European Medicines Agency. Assessment report: Kalydeco (ivacaftor). 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002494/WC500130766.pdf (Accessed 21 Aug 2013).

  6. Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2002;35(3):246–59.

    Article  PubMed  Google Scholar 

  7. Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187(7):680–9.

    Article  PubMed  Google Scholar 

  8. Cystic Fibrosis Trust. Standards for the clinical care of children and adults with cystic fibrosis in the UK; 2011. http://www.cftrust.org.uk/aboutcf/publications/consensusdoc/CF_Trust_Standards_of_Care_2011_%28website_Apr_12%29.pdf (Accessed 21 Aug 2013).

  9. European Medicines Agency. Kalydeco 150 mg film-coated tablets: summary of product characteristics; 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002494/WC500130696.pdf (Accessed 21 Aug 2013).

  10. US Food and Drug Administration. Kalydeco (ivacaftor) tablets: US prescribing information; 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203188s001lbl.pdf (Accessed 21 Aug 2013).

  11. Eckford PDW, Li C, Ramjeesingh M, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner. J Biol Chem. 2012;287(44):36639–49.

    Article  PubMed  CAS  Google Scholar 

  12. Van Goor F, Hadida S, Grootenhuis PDJ, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA. 2009;106(44):18825–30.

    Article  PubMed  Google Scholar 

  13. Yu H, Burton B, Huang C-J, et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros. 2012;11(3):237–45.

    Article  PubMed  CAS  Google Scholar 

  14. Woodworth BA, Zhang S, Skinner D, et al. Comparison of CFTR and ciliary beat frequency activation by the CFTR modulators VX-770, VRT532, and UCCF-152 in primary sinonasal epithelial cultures [abstract no. 114]. Pediatr Pulmonol. 2011;46:251–2.

    Google Scholar 

  15. Jih KY, Hwang TC. Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle. Proc Natl Acad Sci USA. 2013;110(11):4404–9.

    Article  PubMed  CAS  Google Scholar 

  16. Van Goor F, Yu H, Burton B, et al. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros. 2013. doi:10.1016/j.jcf.2013.06.008.

    Google Scholar 

  17. Pohl K, Reeves EP, McElvaney NG. The CFTR potentiator ivacaftor corrects defective degranulation of secondary and tertiary granules by cystic fibrosis neutrophils [abstract no. WS9.9]. J Cyst Fibros. 2012;11(Suppl. 1):S21.

    Article  Google Scholar 

  18. Davies JC, Sheridan H, Lee P, et al. Lung clearance index to evaluate the effect of ivacaftor on lung function in subjects with CF who have the G551D-CFTR mutation and mild lung disease [abstract no. 249]. Pediatr Pulmonol. 2012;47:311.

    Article  Google Scholar 

  19. Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010;363(21):1991–2003.

    Article  PubMed  CAS  Google Scholar 

  20. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663–72 (plus supplementary appendix).

    Google Scholar 

  21. Davies JC, Wainwright CE, Canny GJ, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med. 2013;187(11):1219–25 (plus supplementary appendix).

    Google Scholar 

  22. Altes T, Johnson MA, Miller GW, et al. Hyperpolarized gas MRI of ivacaftor therapy in persons with cystic fibrosis and the G551D-CFTR mutation [abstract no. 196]. Pediatr Pulmonol. 2012;47:291.

    Google Scholar 

  23. Li C, Song T, Ordonez C, et al. No effect of therapeutic and supratherapeutic doses of ivacaftor on QTc interval in healthy subjects [abstract no. PII-66]. Clin Pharmacol Ther. 2013;93(S1):S76.

    Google Scholar 

  24. Hayes E, Pohl K, McElvaney NG, et al. The cystic fibrosis neutrophil: a specialized yet potentially defective cell. Arch Immunol Ther Exp (Warsz). 2011;59(2):97–112.

    Article  Google Scholar 

  25. Zha J, Zhang J, Ordonez C. Pharmacokinetics (PK), metabolism and excretion of [14C] VX-770, a potentiator of cystic fibrosis transmembrane conductance regulator (CFTR), in healthy subjects [abstract no. 1124131]. J Clin Pharmacol. 2011;51(9):1358–9.

    Google Scholar 

  26. Zha J, Kumor K, Zhang J, et al. Exposure–response relationship for FEV1 and sweat chloride in patients with cystic fibrosis treated with ivacaftor, a CFTR potentiator [abstract no. 235]. Pediatr Pulmonol. 2012;47:306.

    Google Scholar 

  27. Zha J, Zhang J, Ordonez C, et al. Clinical pharmacology profile of ivacaftor, a CFTR potentiator [abstract no. 236]. Pediatr Pulmonol. 2012;47:306–7.

    Google Scholar 

  28. Vertex Pharmaceuticals Incorporated. Study of ivacaftor in cystic fibrosis subjects aged 12 years and older with the G551D mutation (STRIVE) [ClinicalTrials.gov identifier NCT00909532]. US National Institutes of Health, ClinicalTrials.gov; 2013. http://www.clinicaltrials.gov (Accessed 21 Aug 2013).

  29. Vertex Pharmaceuticals Incorporated. Study of ivacaftor in cystic fibrosis subjects aged 6 to 11 years with the G551D mutation (ENVISION) [ClinicalTrials.gov identifier NCT00909727]. US National Institutes of Health, ClinicalTrials.gov; 2012. http://www.clinicaltrials.gov (Accessed 21 Aug 2013).

  30. McKone E, Li H, Gilmartin G, et al. Long-term safety and efficacy of ivacaftor in persons with cystic fibrosis who have the G551D-CFTR mutation [abstract no. 211]. Pediatr Pulmonol. 2012;47(S35):296–7.

    Google Scholar 

  31. Quittner A, Ramsey B, Rodriguez S, et al. Patient-reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D-CFTR mutation [abstract no. 212]. Pediatr Pulmonol. 2012;47:297.

    Google Scholar 

  32. Eakin MN, Bilderback A, Boyle MP, et al. Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cyst Fibros. 2011;10(4):258–64.

    Article  PubMed  Google Scholar 

  33. US National Institutes of Health. ClinicalTrials.gov; 2013. http://www.clinicaltrials.gov (Accessed 21 Aug 2013).

  34. Flume PA, Liou TG, Borowitz DS, et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest. 2012;142(3):718–24.

    Article  PubMed  Google Scholar 

  35. Castellani C, Cuppens H, Macek M Jr, et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros. 2008;7(3):179–96.

    Article  PubMed  CAS  Google Scholar 

  36. Boyle MP, Bell S, Konstan M, et al. The investigational CFTR corrector, VX-809 (lumacaftor) co-administered with the oral potentiator ivacaftor improved CFTR and lung function in F508DEL homozygous patients: phase II study results [abstract no. 260]. Pediatr Pulmonol. 2012;47:315.

    Google Scholar 

  37. Boyle MP, Bell S, Konstan MW, et al. VX-809, an investigational CFTR corrector, in combination with VX-770, an investigational CFTR potentiator, in subjects with CF and homozygous for the F508del-CFTR mutation [abstract no. 212]. Pediatr Pulmonol. 2011;46:287.

    Google Scholar 

Download references

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand

    Emma D. Deeks

Authors
  1. Emma D. Deeks
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emma D. Deeks.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Deeks, E.D. Ivacaftor: A Review of Its Use in Patients with Cystic Fibrosis. Drugs 73, 1595–1604 (2013). https://doi.org/10.1007/s40265-013-0115-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-013-0115-2

Keywords

Search

Navigation